Baxter is based in Menlo Park, California and will focus on advising clients on advisory and capital raising activities in the Life Sciences sector.
Baxter was most recently a Senior Managing Director at Bank of America Merrill Lynch as Head of their West Coast Life Sciences coverage effort. With over 17 years of investment banking experience across strategic advisory, equity capital markets and debt capital markets, Baxter brings a wealth of experience and expertise to investment banking clients in healthcare. He has advised his clients on a number of notable strategic transactions, including BioMarin’s acquisition of Prosensa, the sale of Furiex to Forest Laboratories, the sale of Ardea to AstraZeneca, the separation of Theravance Biopharma from Theravance, Inc. and Gilead’s acquisition of Pharmasset and on capital markets transactions for the aforementioned clients and numerous others including equity offerings, convertible debt, traditional debt and royalty financings. Baxter began his financial services career in 1991 as a bank examiner for the FDIC.
Roger Altman, Evercore’s Executive Chairman, said, 'We are extraordinarily pleased to have a banker of Ed’s quality and experience join Evercore to further strengthen our world-class Healthcare team, which recently has advised Centene on its $6.8bn acquisition of Health Net, CVS Health on its $12.7bn acquisition of Omnicare, Sun Pharma on its $4bn acquisition of Ranbaxy, and AstraZeneca on Pfizer’s unsolicited offer, among other transactions. He will help us expand our advisory and capital markets efforts in Life Sciences, particularly on the West Coast, allowing us to add to an already impressive list of Healthcare clients'.
Ralph Schlosstein, Evercore’s President and Chief Executive Officer, said, 'Healthcare represents one of the largest and most active industries for investment banking services. Ed is a critically important addition to our extremely talented healthcare advisory and capital markets team. He brings a solid network of relationships, extensive transaction experience and a strong reputation for integrity, thoughtfulness and objective advice. The decision to hire Ed is consistent with our commitment to provide the highest quality advice across all key sectors and regions of the Healthcare industry'.
Francois Maisonrouge, Senior Managing Director in Evercore’s Healthcare Group added, 'In an era in which biotech is entering its golden age, we are thrilled to add a banker of Ed’s talent to our franchise, which is keenly focused on supporting innovation-based companies. The addition of Ed, combined with the capabilities of Evercore ISI, allows us to serve a broad array of clients, whether in the more traditional pharmaceutical arena or in biotech, on all of their strategic and equity capital raising transactions'.
Baxter commented, 'Evercore's reputation for client focus, quality, independence and differentiated advice is well known in the marketplace. Evercore’s 2014 combination with ISI has created a leading equities franchise which complements its historically strong strategic and debt capital markets advisory business, highly relevant for my clients in Life Sciences. My new Evercore partners and this platform will enable me to provide my clients with unparalleled service on matters of strategic and financial importance. I am excited to join this team'.
Baxter received his MBA from the Wharton School of the University of Pennsylvania and received his B.S. from San Diego State University.